TrishaMichelWise-DraperMDPhD

Oncology • Cincinnati, OH

Head & Neck Cancer

Associate Professor of Medicine, Director of Medical Oncology Services, Medical Director UCCC Clinical Trials Office

Join to view full profile

Dr. Wise-Draper is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wise-Draper's full profile

Already have an account?

Office
234 Goodman St
Ml 0781
Cincinnati, OH 45219
Phone+1 513-584-4505

Education & Training

University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2013
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2011
University of Cincinnati College of MedicineClass of 2010

Certifications & Licensure

OH State Medical License 2010 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma Start of enrollment: 2016 Jan 01
Active, not recruiting
Phase 2
Study of Letrozole in Recurrent Gliomas Start of enrollment: 2017 May 16
Recruiting
Early Phase 1
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy Start of enrollment: 2017 Dec 06
Active, not recruiting
Phase 2
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors Start of enrollment: 2017 Dec 06
Active, not recruiting
Phase 1, Phase 2
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC Start of enrollment: 2020 Nov 04
Active, not recruiting
Phase 2
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients Start of enrollment: 2020 Aug 31
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry
Cancer Cell. 2024-12-09
2 citations
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label,...
Loren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, Julie A Kish, Steven S Chang
The Lancet. Oncology. 2024-12-01
Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma.
Julianna Korns, Christina A Wicker, Maria Lehn, Shreya Shyamsunder, Samuel Thompson
Cancer Letters. 2024-12-01

Press Mentions

University of Cincinnati Cancer Experts Present Research at ASCO Annual MeetingMay 25th, 2023
Researchers Find Ways Immunotherapy Affects COVID-19 OutcomesNovember 6th, 2022
A Potential New Treatment for Brain TumorsSeptember 23rd, 2022
Join now to see all